COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020

COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020

Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine...

Full description

Bibliographic Details
Main Authors: François Bénézit, Audrey Le Bot, Stéphane Jouneau, Florian Lemaître, Charlotte Pronier, Pierre-Axel Lentz, Solène Patrat-Delon, Matthieu Revest, Vincent Thibault, Pierre Tattevin
Format: Article
Language:English
Published: Centers for Disease Control and Prevention 2020-10-01
Series:Emerging Infectious Diseases
Subjects:
COVID-19
2019 novel coronavirus disease
hydroxychloroquine
plasma concentration
sarcoidosis
France
Online Access:https://wwwnc.cdc.gov/eid/article/26/10/20-1816_article
id doaj-5e8e4a3a9ff6450689be81e3c46f7d8a
record_format Article
spelling doaj-5e8e4a3a9ff6450689be81e3c46f7d8a2020-11-25T03:41:48ZengCenters for Disease Control and PreventionEmerging Infectious Diseases1080-60401080-60592020-10-0126102513251510.3201/eid2610.201816COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020François BénézitAudrey Le BotStéphane JouneauFlorian LemaîtreCharlotte PronierPierre-Axel LentzSolène Patrat-DelonMatthieu RevestVincent ThibaultPierre TattevinBecause of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19 despite adequate plasma concentrations.https://wwwnc.cdc.gov/eid/article/26/10/20-1816_articleCOVID-192019 novel coronavirus diseasehydroxychloroquineplasma concentrationsarcoidosisFrance
collection DOAJ
language English
format Article
sources DOAJ
author François Bénézit
Audrey Le Bot
Stéphane Jouneau
Florian Lemaître
Charlotte Pronier
Pierre-Axel Lentz
Solène Patrat-Delon
Matthieu Revest
Vincent Thibault
Pierre Tattevin
spellingShingle François Bénézit
Audrey Le Bot
Stéphane Jouneau
Florian Lemaître
Charlotte Pronier
Pierre-Axel Lentz
Solène Patrat-Delon
Matthieu Revest
Vincent Thibault
Pierre Tattevin
COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
Emerging Infectious Diseases
COVID-19
2019 novel coronavirus disease
hydroxychloroquine
plasma concentration
sarcoidosis
France
author_facet François Bénézit
Audrey Le Bot
Stéphane Jouneau
Florian Lemaître
Charlotte Pronier
Pierre-Axel Lentz
Solène Patrat-Delon
Matthieu Revest
Vincent Thibault
Pierre Tattevin
author_sort François Bénézit
title COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
title_short COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
title_full COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
title_fullStr COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
title_full_unstemmed COVID-19 in Patient with Sarcoidosis Receiving Long-Term Hydroxychloroquine Treatment, France, 2020
title_sort covid-19 in patient with sarcoidosis receiving long-term hydroxychloroquine treatment, france, 2020
publisher Centers for Disease Control and Prevention
series Emerging Infectious Diseases
issn 1080-6040
1080-6059
publishDate 2020-10-01
description Because of in vitro studies, hydroxychloroquine has been evaluated as a preexposure or postexposure prophylaxis for coronavirus disease (COVID-19) and as a possible COVID-19 curative treatment. We report a case of COVID-19 in a patient with sarcoidosis who was receiving long-term hydroxychloroquine treatment and contracted COVID-19 despite adequate plasma concentrations.
topic COVID-19
2019 novel coronavirus disease
hydroxychloroquine
plasma concentration
sarcoidosis
France
url https://wwwnc.cdc.gov/eid/article/26/10/20-1816_article
work_keys_str_mv AT francoisbenezit covid19inpatientwithsarcoidosisreceivinglongtermhydroxychloroquinetreatmentfrance2020
AT audreylebot covid19inpatientwithsarcoidosisreceivinglongtermhydroxychloroquinetreatmentfrance2020
AT stephanejouneau covid19inpatientwithsarcoidosisreceivinglongtermhydroxychloroquinetreatmentfrance2020
AT florianlemaitre covid19inpatientwithsarcoidosisreceivinglongtermhydroxychloroquinetreatmentfrance2020
AT charlottepronier covid19inpatientwithsarcoidosisreceivinglongtermhydroxychloroquinetreatmentfrance2020
AT pierreaxellentz covid19inpatientwithsarcoidosisreceivinglongtermhydroxychloroquinetreatmentfrance2020
AT solenepatratdelon covid19inpatientwithsarcoidosisreceivinglongtermhydroxychloroquinetreatmentfrance2020
AT matthieurevest covid19inpatientwithsarcoidosisreceivinglongtermhydroxychloroquinetreatmentfrance2020
AT vincentthibault covid19inpatientwithsarcoidosisreceivinglongtermhydroxychloroquinetreatmentfrance2020
AT pierretattevin covid19inpatientwithsarcoidosisreceivinglongtermhydroxychloroquinetreatmentfrance2020
_version_ 1724528184724029440

Similar Items